Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection

Hepatitis C virus (HCV) genotypes 1 and 3 are together responsible for approximately 70% of an estimated 71 million to 80 million HCV infections worldwide. Direct-acting antiviral agents have become the standard-of-care treatment for chronic HCV infection and show high rates of sustained virologic…

http://ift.tt/2BrQwEz